Chris@NNW, Author at NetworkNewsWire

WednesdayJun 10, 2020 10:20 am

Medexus Pharmaceuticals Inc. (TSX.V: MDP) Featured in Virtual Coverage of the Summer Investor Summit 2020

Medexus (TSX.V: MDP) is a leading specialty pharmaceutical company with a strong North American commercial platform. The company's vision is to provide the best healthcare products to healthcare professionals and patients, through its core values of quality, innovation, customer service and teamwork. Medexus is focused on the therapeutic areas of auto-immune disease, hematology and allergy. The company's leading products are: IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to…

WednesdayJun 10, 2020 10:20 am

Tinybeans Group Limited (TNYYF) Featured in Virtual Coverage of the Summer Investor Summit 2020

Tinybeans Group Limited (OTC: TNYYF) is a Sydney and New York-based, social media platform focused on enabling families and friends to connect and share moments with each other. The company began around the virtues that everyone in the family, no matter who they are, should celebrate the everyday moments of the children in the family. Each family member can then love and comment on these moments. The company started in Sydney in 2012 as a solution for sharing of family moments on a secure and private social media platform and now services users in across over 160 countries. For more…

WednesdayJun 10, 2020 9:45 am

Medicenna Therapeutics Corp. (TSX: MDNA) (OTCQB: MDNAF) Featured in Virtual Coverage of the Summer Investor Summit 2020

Medicenna Therapeutics (TSX: MDNA) (OTCQB: MDNAF) is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers. Medicenna's long-acting IL2 Superkine assets, MDNA19 and MDNA11, are best-in-class next-generation IL-2WEs in development with superior CD122 binding without CD25 affinity and therefore preferentially stimulating cancer killing effector T cells and NK cells when compared to competing IL-2 programs. It is anticipated that MDNA19 or MDNA11 will be ready for the clinic in 2021. For more information, visit…

WednesdayJun 10, 2020 9:45 am

Western Magnesium (MLYF) Featured in Virtual Coverage of the Summer Investor Summit 2020

Western Magnesium's (OTCQB: MLYF) goal is to be a low-cost producer of green, primary magnesium metal, a strategic commodity prized for its strength and light weight. Unlike outdated and costly production processes, Western Magnesium looks to use a continuous silicothermic process to produce magnesium, which significantly reduces labor and energy costs relative to current methods and processes, while being environmentally friendly. For more information, visit the company's website at www.westmagcorp.com To view IBN’s virtual coverage of the Summer Investor Summit, visit http://IBN.fm/InvestorSummitSummer2020 About InvestorBrandNetwork’s Virtual Coverage The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online…

TuesdayJun 09, 2020 4:30 pm

Helius Medical Technologies Inc. (TSX: HSM) (NASDAQ: HSDT) Featured in Virtual Coverage of the Summer Investor Summit 2020

Helius Medical Technologies (TSX: HSM) (NASDAQ: HSDT) is a neurotech company focused on neurological wellness. The company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The company's first product in development is the Portable Neuromodulation Stimulator (PoNS™). The stimulator delivers neurostimulation via the tongue, which has been shown in clinical studies to improve the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. For more information, visit the company's website at www.heliusmedical.com To view IBN’s virtual coverage of…

TuesdayJun 09, 2020 4:30 pm

Avalon Advanced Materials Inc. (AVLNF) Featured in Virtual Coverage of the Summer Investor Summit 2020

Avalon Advanced Materials Inc. (OTCQB: AVLNF) is a Canadian mineral development company specializing in sustainably produced materials for clean technology. The company now has four advanced stage projects, providing investors with exposure to lithium, tin and indium, as well as rare earth elements, tantalum, cesium and zirconium. Avalon is currently focusing on developing its Separation Rapids Lithium Project near Kenora, Ontario, while looking at several new project opportunities, including reactivating its 100%-owned Lilypad Tantalum-Cesium Project in northwestern Ontario. Social responsibility and environmental stewardship are corporate cornerstones. For more information, visit the company's website at www.avalonadvancedmaterials.com To view IBN’s virtual coverage…

TuesdayJun 09, 2020 3:55 pm

Marrone Bio Innovations Inc. (NASDAQ: MBII) Featured in Virtual Coverage of the Summer Investor Summit 2020

Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI's pro-farm, Finland-based subsidiary employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. For more information, visit the company's website at www.marronebio.com To view IBN’s virtual coverage of the Summer Investor Summit, visit http://IBN.fm/InvestorSummitSummer2020 About InvestorBrandNetwork’s Virtual…

TuesdayJun 09, 2020 3:55 pm

Alimera Sciences Inc. (NASDAQ: ALIM) Featured in Virtual Coverage of the Summer Investor Summit 2020

Alimera Sciences Inc. (NASDAQ: ALIM) is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people globally. Alimera recently initiated the company's Phase 4 NEW DAY clinical trial, a randomized, controlled, multi-center study designed to generate prospective data for ILUVIEN(R) (fluocinolone acetonide intravitreal implant) 0.19 mg as a baseline therapy in patients diagnosed with diabetic macular edema (DME). For more…

TuesdayJun 09, 2020 3:20 pm

VIQ Solutions Inc. (TSX.V: VQS) (OTCQX: VQSLF) Featured in Virtual Coverage of the Summer Investor Summit 2020

VIQ Solutions (TSX.V: VQS) (OTCQX: VQSLF) is a global expert in video capture software and audio recording with voice-to-text capabilities. VIQ provides a cyber-secure AI technology and service platform to law enforcement, immigration, medical, legal, insurance, courts, and transcription service providers, enabling them to unlock the value of their enterprise digital media and streamline their document-creation workflow, using artificial intelligence tools for measurable business gains. For more information, visit the company's website at www.viqsolutions.com To view IBN’s virtual coverage of the Summer Investor Summit, visit http://IBN.fm/InvestorSummitSummer2020 About InvestorBrandNetwork’s Virtual Coverage The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company,…

TuesdayJun 09, 2020 3:20 pm

PDS Biotechnology Corporation (NASDAQ: PDSB) Featured in Virtual Coverage of the Summer Investor Summit 2020

PDS Biotech (NASDAQ: PDSB) is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific proteins for in vivo uptake and processing by the immune system, while also activating the critical type 1 interferon immunological pathway. This results in the production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Author: Chris@NNW